206 related articles for article (PubMed ID: 28675545)
1. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
Ding H; Fang L; Xin W; Tong Y; Zhou Q; Huang P
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28675545
[TBL] [Abstract][Full Text] [Related]
2. First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
Liao W; Huang J; Wu Q; Wen F; Zhang N; Zhou K; Bai L; Li Q
Breast Cancer; 2020 May; 27(3):399-404. PubMed ID: 31853795
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
4. Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
Huang X; Weng X; Lin S; Liu Y; Luo S; Wang H; Ming WK; Huang P
BMJ Open; 2020 Aug; 10(8):e036107. PubMed ID: 32868353
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model.
Lux MP; Hartmann M; Jackisch C; Raab G; Schneeweiss A; Possinger K; Oyee J; Harbeck N
Breast Cancer Res Treat; 2009 Sep; 117(2):305-17. PubMed ID: 19130218
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom.
Das R; Cope S; Ouwens M; Turner P; Howlett M
Clin Ther; 2013 Mar; 35(3):246-260.e5. PubMed ID: 23453402
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer].
Sasse AD; Sasse EC
Rev Assoc Med Bras (1992); 2009; 55(5):535-40. PubMed ID: 19918652
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Lipsitz M; Delea TE; Guo A
Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
[TBL] [Abstract][Full Text] [Related]
10. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Moeremans K; Annemans L
Int J Gynecol Cancer; 2006; 16 Suppl 2():576-8. PubMed ID: 17010076
[TBL] [Abstract][Full Text] [Related]
12. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
Noguchi S; Ellis MJ; Robertson JFR; Thirlwell J; Fazal M; Shao Z
Breast Cancer; 2018 May; 25(3):356-364. PubMed ID: 29450827
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
Mansel R; Locker G; Fallowfield L; Benedict A; Jones D
Br J Cancer; 2007 Jul; 97(2):152-61. PubMed ID: 17622238
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Jones SE; Pippen J
Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S9-14. PubMed ID: 15865850
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil.
Fonseca M; Araújo GT; Saad ED
Rev Assoc Med Bras (1992); 2009; 55(4):410-5. PubMed ID: 19750307
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
Simons WR; Jones D; Buzdar A
Clin Ther; 2003 Nov; 25(11):2972-87. PubMed ID: 14693319
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Matter-Walstra K; Ruhstaller T; Klingbiel D; Schwenkglenks M; Dedes KJ
Breast Cancer Res Treat; 2016 Jul; 158(1):51-57. PubMed ID: 27277747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]